SerpApi.Org
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is often described as the "bible" of psychiatric diagnosis. It shapes how clinicians diagnose patients, how insurers reimburse care, how researchers design psychiatric studies, and how pharmaceutical companies develop and market treatments. Yet, the very authority that gives the DSM its power also raises the question of who shapes the DSM, which will reverberate even more consequentially as the field prepares for the rollout of DSM-6 in several years.
Analyses of the DSM-5 revision process (DSM-5-TR) bring this question into sharper focus. A 2024 BMJ cross-sectional study found that approximately 60% of U.S.-based physicians involved in DSM-5-TR panels or task forces received industry payments, totaling more than $14 million between 2016 and 2019. The payments varied widely, from research funding to consulting fees and free meals. At first glance, the payments may appear unsurprising in an era when academia and industry are deeply intertwined. But when those relationships intersect with the creation of diagnostic criteria, the implications become far more important.
To be clear, financial ties do not equate to misconduct. The presence of a conflict of interest does not prove that any individual acted inappropriately or that DSM-5-TR revisions were biased. Leaders involved in the DSM-5-TR revision have argued that conflicts were disclosed, reviewed, and managed, with safeguards in place to prevent undue influence. They also note that DSM-5-TR is a diagnostic manual, not a treatment guideline, suggesting that its content offers limited direct benefit to industry.
Yet, this defense may not fully address the deeper concern. The issue is less about overt corruption and more about subtle influence. A substantial body of research suggests that even small gifts can shape decision-making in ways that are difficult for individuals to perceive in themselves. The BMJ analysis reinforces this point: the most common payments to DSM contributors were for food and beverages, precisely the type of low-value interaction most likely to escape scrutiny while still influencing behavior.
Medicine has long relied on disclosure as the primary mechanism for managing conflicts of interest. The assumption is that transparency allows others to judge the credibility of recommendations. But growing evidence suggests that disclosure alone may be insufficient and may even normalize conflicts rather than mitigate them. When financial ties become ubiquitous, they risk being perceived as inevitable rather than problematic.
The DSM is a unique and strategic document. Unlike clinical practice guidelines, which explicitly recommend treatments, the DSM defines the boundaries of illness itself. These definitions carry enormous downstream effects. Expanding diagnostic criteria can increase the number of individuals eligible for treatment, influence prescribing patterns, and shape research priorities. Even seemingly minor changes, such as adjusting symptom thresholds or age-of-onset criteria, can have population-level consequences.
Critics argue that this creates fertile ground for "diagnostic expansion," sometimes referred to as disease mongering. They point to historical examples in which broadened criteria have been associated with increased diagnosis and treatment rates. In fact, since DSM-III, the number of recognized disorders, subtypes, and specifiers has steadily expanded, accompanied by broader diagnostic thresholds and categories that have brought millions more people under the umbrella of psychiatric diagnoses.
At the same time, it would be naïve to assume that eliminating all conflicts of interest is either feasible or desirable. Many leading experts in psychiatry collaborate with industry in ways that advance science and patient care. Research funding often flows through academic institutions and supports important clinical trials. Excluding all individuals with any industry relationship could risk excluding precisely those with the most relevant expertise.
This tension between expertise and independence will define the credibility of DSM-6, and unless it is resolved, it will carry forward the same questions about trust, transparency, and influence that now shadow DSM-5-TR. The Institute of Medicine has long recommended that guideline panels be composed primarily of individuals free of financial conflicts, with conflicted experts serving in advisory rather than decision-making roles. The BMJ study echoes this recommendation, calling for a "rebuttable presumption" against including individuals with industry ties in decision-making positions.
But implementing such a model raises practical challenges. Who qualifies as sufficiently independent? How should different types of payments be weighted? Is research funding equivalent to consulting fees? And perhaps most importantly, how do we ensure that any new system maintains both credibility and competence?
The current debate also highlights a broader issue: transparency in process. Critics have noted that the American Psychiatric Association does not publicly release detailed records of deliberations or the rationale behind specific changes. Without this level of transparency, it becomes difficult for outside observers to assess whether conflicts of interest may have influenced decisions. Greater openness, such as publishing meeting minutes or providing detailed justifications for revisions, could help bridge this gap.
There is also an opportunity to rethink how we conceptualize diagnostic authority. The DSM has traditionally relied on expert consensus, a model that has served psychiatry well in establishing reliability but has been criticized for insufficient integration of systematic evidence review. Moving toward a more explicitly evidence-based framework, one that incorporates systematic reviews, graded evidence, and broader stakeholder input, could enhance both the scientific rigor and public trust of future revisions.
Trust in medicine is not built solely on the absence of wrongdoing; it is built on the perception of fairness, transparency, and independence. When most individuals shaping diagnostic criteria have financial ties to industry -- even if those ties are appropriately disclosed and managed -- it invites scrutiny. And in a field like psychiatry, where diagnosis is fluid and boundaries are evolving, that scrutiny is both inevitable and necessary.
The DSM is too important to be above questioning. Its authority depends not only on the expertise of its contributors but also on the integrity of its process. Strengthening that process through greater independence, transparency, and methodological rigor is not an indictment of psychiatry. It is an investment in its future. The goal is not to sever the relationship between psychiatry and industry, but to recalibrate it and ensure that when we define mental illness, we are guided first and foremost by evidence, clinical wisdom, and the needs of patients rather than forces that might pull us off course.
